Tag: clinical study
Anaphylm™, Aquestive’s Needleless Sublingual Epinephrine, Takes Another Step Forward
Company reports positive topline results from phase 2 study.
Sublingual Epinephrine Faster to Maximum Concentration than Auto-Injector, Syringe
Researchers observed early and robust increases in systolic and diastolic blood pressure and pulse with AQST-109.
Aquestive’s Sublingual Epinephrine Achieves Therapeutic Blood Concentrations Following Administration
Company presented top level Phase 1 results at #AAAAI2022 meeting.
Vanderbilt Recruiting Children to Study Allergic Responses to COVID-19 mRNA Vaccines
Participating children will be closely monitored and observed by qualified staff at a children’s hospital.
Intranasal Delivery of Emergency Epinephrine Takes Another Step Toward Realization
Another company is reporting promising results in the race to bring an intranasal device to market.
Results of Aimmune’s Pivotal Phase 3 European Trial of PALFORZIA® Published...
Peanut-allergic patients treated with Palforzia showed desensitization to peanut protein with a predictable safety profile at nine months
FDA Approves Dupixent® as First Biologic for Treatment of Children Aged...
Three-quarters of patients receiving Dupixent achieved at least a 75% improvement in overall disease, with an average improvement of approximately 80%.
Study: Intranasal Epinephrine Absorbed Faster Than Injection and Even Better with...
Study compared absorption of epinephrine via nasal spray to that of intramuscular injection.
DBV Technologies Reports Positive Three-Year, Long Term Data from Phase III...
Patients demonstrated durable, long-term clinical benefit with an additional two years of treatment.
